Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study

Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
K SawadaToshifumi Hibi

Abstract

Nafamostat mesilate is the first anticoagulant of choice for leukocytapheresis (LCAP) with a Cellsorba E column for treating ulcerative colitis (UC). However, because of complications, mainly due to allergy to nafamostat mesilate, heparin may be used as a substitute. To evaluate the safety and tolerability of nafamostat mesilate and heparin as anticoagulants in LCAP for UC, we conducted post hoc analysis of data from a large-scale, prospective, observational study of LCAP, which was conducted at 116 medical facilities in Japan between May 2010 and December 2012. Of 832 patients included in this analysis, nafamostat mesilate and heparin were used in 676 (81.3%) and 113 (13.6%), respectively. There were no significant differences in the incidence of adverse reactions (8.6% vs. 7.1%) and intrafilter pressure increases (12.7% vs. 16.8%) between the nafamostat mesilate and heparin groups. Adverse reactions of hemorrhage or blood pressure decreases associated with heparin use were not observed. There were no significant differences in rates of clinical remission (69.1% vs. 68.1%) and mucosal healing (62.9% vs. 63.6%) between the nafamostat mesilate and heparin groups. Thus, the safety and tolerability were comparable in the nafamosta...Continue Reading

References

Dec 24, 1987·The New England Journal of Medicine·K W SchroederD M Ilstrup
Jun 30, 1994·The New England Journal of Medicine·S LichtigerS Hanauer
May 4, 1999·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·K NagaseT Shimoyama
Aug 2, 2001·Journal of Critical Care·H Iwama
Jan 10, 2002·Clinical Microbiology Reviews·Barbara A HendricksonJudy H Cho
Nov 3, 2005·Nature Clinical Practice. Gastroenterology & Hepatology·Toshifumi Hibi, Atsushi Sakuraba
Dec 13, 2005·The New England Journal of Medicine·Paul RutgeertsJean Frédéric Colombel
Mar 25, 2006·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Shinya AshizukaTanenao Eto
Nov 1, 2006·Critical Care Medicine·Lena M NapolitanoStanley A Nasraway
Sep 6, 2007·Blood Purification·Kazunari KankeHideyuki Hiraishi
Feb 3, 2009·The American Journal of Medicine·Stuart L Silverman

❮ Previous
Next ❯

Citations

May 22, 2020·World Journal of Gastrointestinal Pathophysiology·Xiu-Li ChenYing-De Wang
Jul 1, 2020·Neural Regeneration Research·George Zaki Ghali, Michael George Zaki Ghali
Oct 9, 2020·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Yoh IshiguroMasahiro Iizuka
Oct 29, 2020·ACS Infectious Diseases·Anil Mathew TharappelHongmin Li
Aug 14, 2021·JGH Open : an Open Access Journal of Gastroenterology and Hepatology·Mingming Zhu, Zhihua Ran

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

La Presse médicale
Dominique Cazals-Hatem
Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Shinya AshizukaTanenao Eto
© 2022 Meta ULC. All rights reserved